| Literature DB >> 26950470 |
Ya-Chih Tien1, Ying-Ming Chiu1,2, Mei-Ping Liu1.
Abstract
OBJECTIVE: To determine the frequency of lost to follow-up (LTFU) in the setting of usual care for outpatients with rheumatic diseases including RA, SLE, AS, and Ps/PsA, to explore the associated demographic factors, and to investigate the reasons for being LTFU from the original medical care.Entities:
Mesh:
Year: 2016 PMID: 26950470 PMCID: PMC4780692 DOI: 10.1371/journal.pone.0150816
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Demographic profile of the cohort patients.
| RA | SLE | AS | Ps/PsA | |
|---|---|---|---|---|
| Number of patients, n (%) | 406 (52) | 174 (22.3) | 136 (17.4) | 65 (8.3) |
| Age, years, (mean±SD) | 58.3±13.9 | 39.7±14.1 | 38.4±13.4 | 51.9±15.4 |
| Female gender, n (%) | 317 (78.1) | 155 (89.1) | 25 (18.4) | 32 (49.2) |
RA: rheumatoid arthritis, SLE: systemic lupus erythematosus, AS: ankylosing spondylitis, Ps/PsA: psoriasis/psoriatic arthritis
Fig 1The frequency of LTFU in the four rheumatic diseases.
*The p value (chi-squared test) evaluated the association between the four rheumatic diseases and being potential LTFU. The percentage (%) represent the proportion of follow-up status in each disease. The frequency of LTFU is represented by braces. RFU: regularly follow-up, LTFU: lost to follow-up.
Baseline demographic characteristics associated with LTFU in the four rheumatic diseases.
| RFU | LTFU | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|---|
| OR (95% CI) | P value | OR (95% CI) | P value | ||||
| No. of patients | 309 | 97 | — | — | — | ||
| Age, years (mean±SD) | 57.49±13.30 | 60.85±15.41 | 1.02 (1.00–1.04) | 0.039 | 1.02 (1.00–1.04) | 0.033 | |
| Female, n (%) | 239 (77.35) | 78 (80.41) | 1.20 (0.68–2.12) | 0.525 | 1.27 (0.72–2.25) | 0.415 | |
| No. of patients | 129 | 45 | — | — | — | ||
| Age, years (mean±SD) | 39.54±13.78 | 40.16±15.11 | 1.00 (0.98–1.03) | 0.801 | 1.01 (0.98–1.03) | 0.622 | |
| Female, n (%) | 111 (86.05) | 44 (97.78) | 7.13 (0.92–55.07) | 0.060 | 7.38 (0.95–57.29) | 0.056 | |
| No. of patients | 88 | 48 | — | — | — | ||
| Age, years (mean±SD) | 38.98±13.41 | 37.44±13.55 | 0.99 (0.97–1.02) | 0.522 | 0.99 (0.97–1.02) | 0.548 | |
| Female, n (%) | 15 (17.05) | 10 (20.83) | 1.28 (0.53–3.12) | 0.586 | 1.25 (0.51–3.07) | 0.620 | |
| No. of patients | 42 | 23 | — | — | — | ||
| Age, years (mean±SD) | 54.88±16.30 | 46.52±12.40 | 0.96 (0.93–1.00) | 0.042 | 0.96 (0.92–0.99) | 0.021 | |
| Female, n (%) | 18 (42.86) | 14 (60.87) | 2.07 (0.74–5.85) | 0.168 | 2.82 (0.91–8.67) | 0.071 | |
RA: rheumatoid arthritis, SLE: systemic lupus erythematosus, AS: ankylosing spondylitis, Ps/PsA: psoriasis/psoriatic arthritis, RFU: regularly followed-up, LTFU: lost to follow-up.
OR: odds ratio, CI: confidence interval.
a P values were calculated using logistic regression analysis.
*A p value < 0.05 was considered to be significant.
Fig 2Traced reasons for LTFU.
The figure illustrates the proportion of the reasons for LTFU in the four rheumatic diseases.